| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -53,089 | -46,061 | -42,217 | -74,173 |
| Depreciation and amortization expense | 119 | 187 | 43 | 260 |
| Non-cash lease expense | 301 | 301 | 300 | 575 |
| Non-cash interest income on marketable securities | 1,273 | -11,427 | 1,321 | 3,814 |
| Stock-based compensation expense, including employee stock purchase plan expense | 10,148 | 4,266 | 4,250 | 9,070 |
| Prepaid expenses and other current assets | -2,597 | 4,458 | -347 | 1,307 |
| Other assets and long-term deposits | 100 | 496 | 3,911 | 1,738 |
| Accounts payable | -5,681 | 5,773 | 2,391 | -3,566 |
| Other current liabilities | 1,304 | 3,631 | 5,902 | 1,451 |
| Operating lease liabilities | -313 | -313 | -311 | -620 |
| Net cash used in operating activities | -45,987 | -38,327 | -34,527 | -73,862 |
| Purchase of equipment | NaN | NaN | 0 | 0 |
| Maturities of marketable securities | 74,470 | 91,168 | 88,925 | 164,869 |
| Purchases of marketable securities | 69,941 | 253,352 | 71,652 | 175,718 |
| Net cash provided by (used in) investing activities | 4,529 | -162,184 | 17,273 | -10,849 |
| Proceeds from issuance of shares upon follow-on public offering, net of issuance costs of 13,110 | NaN | 205,390 | NaN | NaN |
| Payment of issuance costs for shares issued under 2024 private placement | NaN | 0 | 6,514 | NaN |
| Proceeds from borrowings under credit facility (note 13) | NaN | 0 | 0 | 3,000 |
| Issuance of shares under at-the-market offering, net of issuance costs of 25 | 41,918 | NaN | 0 | 0 |
| Proceeds from issuance of common stock under employee stock purchase plan | NaN | 282 | 0 | 748 |
| Issuance costs for shares issued under november 2025 follow-on offering | 237 | NaN | NaN | NaN |
| Proceeds from exercise of stock options | 8,430 | 7,880 | 41 | 470 |
| Issuance costs for shares issued under 2024 equity private placement | NaN | NaN | NaN | 6,514 |
| Tax withholding for stock options exercised | 4,407 | NaN | NaN | NaN |
| Net cash provided by financing activities | 45,704 | 213,552 | 41 | -2,296 |
| Net increase (decrease) in cash and cash equivalents | 4,246 | 13,041 | -17,213 | -87,007 |
| Cash and cash equivalents at beginning of period | 48,301 | 35,260 | 139,480 | NaN |
| Cash and cash equivalents at end of period | 52,547 | 48,301 | 35,260 | NaN |
Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals, Inc. (OLMA)